Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
Commentary|Videos|August 27, 2025
Redefining Bronchiectasis Research and Management With First FDA Approval
Author(s)Albert Rizzo, MD, James Chalmers, MBChB, PhD
Fact checked by: Victoria Johnson
In this video, the last in a 5-part series, panelists discuss their future outlook on bronchiectasis management.
Advertisement
Advertisement
In the concluding portion of the HCPLive RX Review Special Report, Albert Rizzo, MD, and James Chalmers, MBChB, PhD, discuss how the August 2025
Related to this article
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.
Advertisement
Advertisement